跳至主要内容
临床试验/EUCTR2018-003346-17-DK
EUCTR2018-003346-17-DK进行中(未招募)1 期

Phase III Randomized clinical trial for stage III epithelial ovarian cancer randomizing between primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy:OVHIPEC-2 - OVHIPEC-2

KI-AV0 个研究点目标入组 535 人开始时间: 2020年10月26日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
535

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Female

入选标准

  • - signed and written informed consent
  • - age =18
  • - candidate for primary CRS, in whom a complete cytoreduction, or cytoreducion with no more than 2.5 mm residual disease is considered feasible
  • - histological or cytological proven FIGO stage III primary epithelial ovarian, fallopian tube, or extra-ovarian cancer
  • - fit for major surgery, ASA 1 or ASA 2
  • - WHO performance status 0 t/m2
  • - adequate bone marrow, hepatic and renal function
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 500
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • 1.history of previous malignancies within 5 years prior to inclusion
  • 2.FIGO stage IV disease
  • 3.if complete primary cytoreduction is impossible
  • 4.patients who received prior treatment for the current malignancy

研究者

发起方
KI-AV

相似试验